Gemtuzumab ozogamicin (GO), an anti-CD33 immunoconjugate, was combined with high dose cytarabine (HiDAC; cytarabine 3g/m(2) over 3h daily for 5 days) for adults with relapsed or refractory AML. HiDAC plus GO 9mg/m(2) on day 7 and 4.5mg/m(2) on day 14 was not tolerated, but HiDAC followed by GO 9mg/m(2) on day 7 was safe: 12/37 (32%) patients with relapsed AML achieved complete remission. Median overall survival was 8.9 months. No grade 4 hepatic veno-occlusive disease was observed. This regimen merits further study, both in this setting and as a remission consolidation therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3023007 | PMC |
| http://dx.doi.org/10.1016/j.leukres.2010.07.017 | DOI Listing |
Publication Analysis
Top Keywords
high dose
8
dose cytarabine
8
gemtuzumab ozogamicin
8
patients relapsed
8
relapsed refractory
8
hidac 9mg/m2
8
9mg/m2 day
8
cytarabine gemtuzumab
4
ozogamicin patients
4
refractory acute
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!